Located at the heart of Frankfurt am Main, Speransa Therapeutics is led by a dedicated and highly-specialized team, with a strong background in biopharmaceutical research, development and manufacturing.
The Company is backed by the Boehringer Ingelheim Venture Fund and partners with leading academic institutions such as the University Hospital Tübingen.
Prime-2-CoV_Beta, our lead COVID-19 vaccine candidate, was originally developed at the University of Tübingen, Germany. It is based on a highly attenuated and non-pathogenic live viral vector D1701-VrV derived from an ORF virus isolate. Used for 20 years in biomedical research and veterinary medicine, this vector has highly beneficial characteristics for the development of a COVID-19 vaccine.
The research and development of an innovative, potent and polyvalent COVID-19 vaccine based on the ORF virus as a platform technology for COVID-19 vaccines is a project funded by the EXIST program.
EXIST is a support program of the German Federal Ministry for Economic Affairs and Climate Action (BMWK). It aims at improving the entrepreneurial environment at universities and research institutes as well as increasing the number and success of technology- and knowledge-based business start-ups.
For the last 20 years, the Federal Ministry for Economic Affairs and Energy has been successfully using the “EXIST –Business start-ups in science” program to fund start-up spin-offs from German universities and science.
Through research and development collaborations, partnerships with pharmaceutical and biotech companies, as well as academia and clinics, we aim to fully leverage our technology with cutting edge science and advance vaccine research and development.
Click here to contact us about partnering with Speransa Therapeutics.
.png)
.png)
.png)